Bridgewater Associates LP Sells 31,869 Shares of Phreesia, Inc. (NYSE:PHR)

Bridgewater Associates LP reduced its stake in Phreesia, Inc. (NYSE:PHR) by 51.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,445 shares of the company’s stock after selling 31,869 shares during the quarter. Bridgewater Associates LP’s holdings in Phreesia were worth $694,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PHR. International Assets Investment Management LLC increased its stake in shares of Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after purchasing an additional 1,395 shares during the period. nVerses Capital LLC grew its holdings in Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares in the last quarter. Lombard Odier Asset Management USA Corp bought a new position in Phreesia during the 2nd quarter worth $202,000. Point72 DIFC Ltd acquired a new stake in shares of Phreesia during the second quarter worth $209,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Phreesia during the second quarter worth $301,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Stock Performance

Shares of Phreesia stock opened at $21.10 on Tuesday. The business has a 50-day moving average price of $20.43 and a two-hundred day moving average price of $21.84. Phreesia, Inc. has a 1-year low of $14.55 and a 1-year high of $29.16. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.22 billion, a P/E ratio of -11.72 and a beta of 0.94.

Phreesia (NYSE:PHR) last issued its earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The business had revenue of $102.12 million during the quarter, compared to the consensus estimate of $101.76 million. As a group, analysts anticipate that Phreesia, Inc. will post -1.23 EPS for the current year.

Insider Activity

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,212 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total value of $25,488.36. Following the completion of the sale, the general counsel now owns 119,791 shares of the company’s stock, valued at approximately $2,519,204.73. This trade represents a 1.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Chaim Indig sold 5,295 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $123,108.75. Following the transaction, the chief executive officer now directly owns 1,223,736 shares in the company, valued at $28,451,862. The trade was a 0.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,997 shares of company stock worth $667,943 in the last quarter. 5.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

PHR has been the topic of a number of recent research reports. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Thursday, September 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Phreesia in a report on Thursday, September 5th. Truist Financial increased their price target on Phreesia from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a report on Friday, September 27th. Finally, JPMorgan Chase & Co. increased their target price on Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, September 9th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Phreesia presently has an average rating of “Moderate Buy” and an average target price of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.